ABOUT THIS EPISODE
Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting.
Make sure to check out eXoZymes' website: https://exozymes.com/
Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!
To learn more about BCLA’s events and consulting visit our website.
Follow BCLA on LinkedIn
